672 related articles for article (PubMed ID: 26670548)
1. Central kynurenine pathway shift with age in women.
de Bie J; Guest J; Guillemin GJ; Grant R
J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
[TBL] [Abstract][Full Text] [Related]
2. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
3. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
4. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.
Heyes MP; Saito K; Devinsky O; Nadi NS
Epilepsia; 1994; 35(2):251-7. PubMed ID: 8156942
[TBL] [Abstract][Full Text] [Related]
6. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
7. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
8. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.
Fuertig R; Ceci A; Camus SM; Bezard E; Luippold AH; Hengerer B
Bioanalysis; 2016 Sep; 8(18):1903-17. PubMed ID: 27524289
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
11. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
Heyes MP; Brew BJ; Saito K; Quearry BJ; Price RW; Lee K; Bhalla RB; Der M; Markey SP
J Neuroimmunol; 1992 Sep; 40(1):71-80. PubMed ID: 1387655
[TBL] [Abstract][Full Text] [Related]
12. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
14. Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
Badawy AA
Med Hypotheses; 2018 Sep; 118():129-138. PubMed ID: 30037600
[TBL] [Abstract][Full Text] [Related]
15. CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation.
Yan J; Kothur K; Mohammad S; Chung J; Patel S; Jones HF; Keating BA; Han VX; Webster R; Ardern-Holmes S; Antony J; Menezes MP; Tantsis E; Gill D; Gupta S; Kandula T; Sampaio H; Farrar MA; Troedson C; Andrews PI; Pillai SC; Heng B; Guillemin GJ; Guller A; Bandodkar S; Dale RC
EBioMedicine; 2023 May; 91():104589. PubMed ID: 37119734
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
Saito K; Nowak TS; Markey SP; Heyes MP
J Neurochem; 1993 Jan; 60(1):180-92. PubMed ID: 8417138
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
Rajda C; Galla Z; Polyák H; Maróti Z; Babarczy K; Pukoli D; Vécsei L
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290514
[TBL] [Abstract][Full Text] [Related]
18. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
19. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
20. Sleep disturbance and kynurenine metabolism in depression.
Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]